We have decades of experience in analyzing small and mid-cap stocks as well as disseminating this information to retail investors. With investment cases, we provide free information on investment opportunities within the segment of Nordic small and mid-caps companies for primarily a Nordic investing audience.
If you want to contact us directly, find contact details for the individual employee under Line Up.
Nexcom experienced a 41% drop in revenue in 2022 to DKK 8M and a net loss of DKK 19M (DKK
Biosergen: 1.5 million people die each year from fungal infections. Biosergen, which has FDA orphan drug status, is developing an
After the 2022 annual report and extraordinary general meeting, Ekobot is ready for the partially underwritten rights issue, providing capital
Global demand for food is growing as the global population increases year on year combined with increased consumption. Increased production
Mdundo’s H1 results (July – December 2022) showed continued high growth across all KPIs with 23.4 million active users, 500,000
Danish biotech companies had a tough time in 2022, with Kapital Partners’ Nordic Healthcare index falling by 48% due to
The companies on the Nordic growth exchanges have a reputation for being exciting, but at the same time also being
Ekobot expects to sell 25 of its unique farming robots this year, sign a distribution agreement in the Danish market
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.